Welcome to Eurofins Advinus
A premier preclinical CRO offering drug discovery, preclinical and development stage contract research services including discovery services, CMC services, regulatory Toxicology (Safety Assessment), DMPK and Analytical R&D Services. Eurofins Advinus manufactures drug substances to support Toxicology and clinical studies. With over 30 years of GLP compliance and certification, Eurofins Advinus serves diverse industries such as Biotech, Pharmaceutical, Biological, Agrochemical, Nutraceutical and Cosmetic. Eurofins Advinus is the only contract research organization (CRO) in India to have developed data in support of 100+ end-to-end IND enabling packages to be submitted to global regulators such as USFDA, EMA, MHRA, Health Canada and others.
Eurofins Advinus' ACHIEVEMENTS
YEARS OF
GLP EXPERIENCE
IND PACKAGES
REGULATORY STUDIES
CARCINOGENICITY STUDIES
cGMP CAMPAIGNS IN LAST 5 YEARS
FACILITY TOUR
NEWS AND EVENTS
Tumor Models Boston Summit
Our team members attended the Tumor Models Boston Summit to… more
CASE STUDIES - SEE HOW OUR SCIENCE CAN DRIVE YOUR RESEARCH & DEVELOPMENT
WHAT OUR CLIENTS SAY
-
I am pleased to…
I am pleased to announce that the U.S. Food and Drug Administration (FDA) has approved Tarus Therapeutics’ investigational new drug (IND) application for TT-4, a potentially first-in-class, oral Adenosine A2B receptor (A2BR) Antagonist. I commend Eurofins Advinus team for their highest quality of work and professionalism, understanding of regulatory requirements, and drive to resolve complexities during the TT-4 and TT-10 programs on early development, Chemistry Manufacturing and Controls (CMC) and preclinical IND programs in process optimization and development, ADME, formulation development, toxicology and toxicokinetics which contributed significantly to the timely preparation of a comprehensive data package and completion of the IND applications to the US FDA. It is my pleasure to recommend the highly experienced and enthusiastic Eurofins Advinus team for preclinical drug development and IND-enabling studies.
Sushant Kumar, Co-founder & CEO, Tarus Therapeutics
-
I would say that…
I would say that overall our experience with Eurofins Advinus has been very positive at all times. From the perspective of a small biotech like Origo, Eurofins Advinus fulfils all our requirements: flexibility, adherence to pre agreed timelines, adequate quality for the stage of development and no cost deviations! Our experience with them has been mostly on the IND packages including API and regulatory Toxicology. The approach the team of chemists has always been very proactive, looking for solutions, and keeping in mind the balance of quality vs time which is critical at early stages in development. I would like also like to highlight that, the teams at Eurofins Advinus made a very significant effort to minimize the impact in timelines during the very difficult times of the COVID pandemics,…
Ramon Bosser, CEO, Origo BioPharma
-
I would like to…
I would like to thank the entire Advinus team for their tremendous support in the submission of two INDs with the US FDA. The Advinus team performed multiple in vitro and in vivo IND enabling studies with the highest scientific quality while meeting very aggressive timelines. The Advinus team displayed outstanding scientific competence and professionalism in conducting studies, and the quality of study reports was top notch. Their "can do" attitude was much appreciated and I look forward to collaborating with Advinus in future projects.
Kollol Pal, PhD, MBA – CEO , Pyramid Biosciences, Inc. Waltham, MA, USA
-
I would like to…
I would like to thank the entire Advinus team for their hard work and dedication. Recently, we have worked with Advinus on 2 INDs and both have been successfully submitted to US FDA. Advinus team is very dedicated and deliver a high quality reports and SEND data for IND submission. Team communication is excellent and they have very talented individuals with expertise in their field. I look forward to working with Advinus in future projects.
Vijaypal Reddy, DVM, PhD – Vice President, Nonclinical Safety Assessment, Pyramid BioSciences, Inc. Waltham, MA, USA